a7718v
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
December
06, 2023
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant’s
name)
Building 5, Croxley Park, Hatters Lane
Watford, England, WD18 8YE
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F ✓
Form 40-F
__
Smith+Nephew announces change in Audit Committee Chair
6 December
2023
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology
business, announces
that Rick Medlock has notified the Board of his decision not to
submit himself for re-election as a Non-Executive Director at the
next annual general meeting of the Company.
Jez Maiden, Non-Executive Director, will be appointed Chair of the
Audit Committee with effect from 1 March 2024.
The Board would like to thank Rick for his commitment and
contribution to the Board and the Company and to congratulate Jez
on his new appointment.
Enquiries
Investors / Analysts
Andrew Swift
Smith+Nephew
|
+44 (0) 1923 477433
|
Media
Charles Reynolds
Smith+Nephew
|
+44 (0) 1923 477314
|
Susan Gilchrist / Ayesha Bharmal
Brunswick
|
+44 (0) 20 7404 5959
|
Jez Maiden Biography
Key
skills and competencies
Jez joined the Board in 2023 and has extensive financial experience
across a diverse range of industries and sectors. Jez was Chief
Financial Officer of 5 UK-listed companies over a period of 24
years and has served as a Non-Executive Director on boards of
companies addressing strategic and operational challenges across a
number of different industries, including life-sciences and
healthcare. He was previously Chair of the Audit Committee at
Synthomer PLC and PZ Cussons plc.
Current external appointments
Senior Independent Director, Travis Perkins plc. Non-Executive
Director and member of the Audit Committee at Intertek Group
plc.
Previous experience
Jez retired in 2023 as Group Finance Director at Croda
International plc, the FTSE 100 global speciality chemicals
company, and previously held similar roles at National Express
Group plc and Northern Foods Limited. He has served as the Senior
Independent Director at Synthomer PLC and at both PZ Cussons plc
and Synthomer PLC he chaired the Audit Committee and served on the
Remuneration Committee. He is a fellow of the Chartered Institute
of Management Accountants.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 19,000 employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Advanced Wound Management and
Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on X, LinkedIn, Instagram or Facebook.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
Smith & Nephew plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date:
December 06, 2023
|
By:
|
/s/
Helen Barraclough
|
|
|
Helen
Barraclough
|
|
|
Company
Secretary
|